4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates

4D Molecular Therapeutics (FDMT) reported a Q2 2025 loss of $0.98 per share, wider than the Zacks Consensus Estimate of a $0.88 loss, and revenues of $0.02 million, missing estimates by 98.58%. This marks the fourth consecutive quarter FDMT has failed to surpass consensus EPS estimates, contributing to its year-to-date underperformance against the S&P 500. Despite these misses, the stock retains a Zacks Rank #2 (Buy) based on favorable estimate revisions prior to the earnings release, suggesting potential for near-term market outperformance.

Analysis

4D Molecular Therapeutics (FDMT) reported a significant operational miss for the quarter ended June 2025, with a loss per share of $0.98 against a consensus estimate of $0.88. This loss is also wider than the $0.63 loss reported in the prior-year period. The revenue figure was particularly weak, coming in at just $0.02 million, a 98.58% miss versus consensus, even though it represents an increase from zero revenue a year ago. This marks the fourth consecutive quarter in which the company has failed to surpass consensus EPS estimates, establishing a pattern of under-delivery. This fundamental weakness is reflected in the stock's performance, with a mere 1.1% year-to-date gain, substantially lagging the S&P 500's 8.6% advance. A key point of dissonance is the stock's Zacks Rank #2 (Buy), which was based on a favorable trend in estimate revisions prior to this disappointing release. The outlook is now highly dependent on management's commentary, which will be critical in determining if future consensus estimates, currently at a loss of $0.93 for the next quarter, will be revised downward.

Key Decisions for Investors

• Investors should treat the pre-existing Zacks #2 (Buy) rating with extreme caution, as it was based on data preceding the significant Q2 earnings and revenue miss.
• The primary focus should be on management's commentary during the earnings call to understand the drivers of the massive revenue shortfall and to gauge the credibility of future growth projections.
• Given the consistent failure to meet consensus estimates and significant stock underperformance versus the S&P 500, re-evaluating any long positions is prudent until there is clear evidence of a turnaround in execution.